Odyssey’s IPO Return Comes With a Real Buyer and a Sharper Ask
Odyssey returns to market with TPG support and a cleaner biotech pitch
By Erik Aronesty · Published May 6, 2026 · Odyssey Therapeutics, Inc. · ODTX
BOSTON, May 6, 2026 — Odyssey Therapeutics is not just another biotech terms launch. The Boston company is trying to turn a pulled 2025 IPO into a live Nasdaq debut with a cleaner setup: 13.24 million shares at $16 to $18, a syndicate led by J.P. Morgan, TD Securities and Cantor, and an expected roughly $25 million concurrent private placement from TPG Orazio II that gives the book more visible support than most clinical-stage offerings get at this stage in the amended prospectus. Reuters said the range implies a valuation of as much as about $810 million at the top end.
The more interesting point is what Odyssey is selling. This is not rescue capital. The company said in its May 4 filing that it had about $175.7 million of cash, cash equivalents and marketable securities as of March 31, and it laid out an unusually specific proceeds map: about $135 million to push OD-001 through planned 12-week induction readouts in ulcerative colitis, and about $50 million to move OD-002 through IND-enabling work and a planned Phase 1/2a trial using IPO and private-placement proceeds. For IPO buyers, that reads more like an acceleration financing than a balance-sheet patch.
That does not make the ask cheap. Odyssey reported just $3.0 million of collaboration revenue in 2025 against a $148.6 million net loss, and investors are still being asked to underwrite a mid-stage immunology story before a final prospectus is on file in the S-1/A. The TPG sidecar helps, but the company also says the private placement is not yet under a binding agreement, so the named demand signal is real without being fully locked.
What makes Odyssey worth watching today is the way this return has been staged. The company withdrew its last IPO attempt on June 9, 2025, then raised an oversubscribed $213 million Series D in September. Now it is back with a deeper bank group and a fresh Form 8-A filing dated May 5, a standard late-stage step before trading. The science may be familiar. The question for this deal is whether public investors want to fund a large, cash-rich autoimmune platform on the promise of sharper clinical readouts ahead.